Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 11, 2008, Pages 1796-1801

  Xuan, Qiang ^a   Yang, Xiaoli ^a   Mo, Linjian ^a   Huang, Fengyu ^a   Pang, Youhong ^a   Qin, Min ^a   Chen, Zhiqiang ^a   He, Min ^b   Wang, Qi ^b   Mo, Zeng Nan ^a,b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKOPROTEASE; COMPLEMENTARY DNA; KALLIKREIN 7 PROTEASE; MESSENGER RNA; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ALP GENE; ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; EPITHELIUM CELL; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KLK 7 GENE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

EID: 55549121929     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.1043/1543-2165-132.11.1796     Document Type: Article

References (31)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
2. Lundstrom A, Egelrud T. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm Venereol. 1991;71:471-474.
3. Yousef GM, Scorilas A, Chang A, et al. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate. 2002;51:126-132.
4. Yousef GM, Stephan C, Scorilas A, et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate. 2003;56:287-292.
5. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. J Invest Dermatol. 1993;101:200-204.
6. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986;83:6692-6696.
7. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296-1301.
8. Song X, Zeng L, Jin W, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med. 1999;190:535-542.
9. Franzke CW, Baici A, Bartels J, Christophers E, Wiedow O. Antileukoprotease inhibits stratum corneum chymotryptic enzyme: evidence for a regulative function in desquamation. J Biol Chem. 1996;271:21886-21890.
10. Ohlsson K, Bjartell A, Lilja H. Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl. 1995;16(1):64-74.
11. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000;60:6281-6287.
12. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001;61:3869-3876.
13. Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer. 2000;89:1448-1456.
14. Shigemasa K, Tanimoto H, Underwood LJ, et al. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer. 2001;11:454-461.
15. Tsugaya M, Habib FK, Chisholm GD, et al. Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res. 1996;24:265-271.
16. Habib FK. Regulation of prostate growth in culture with the pollen extract, cernitin T-60 and the impact of the drug on the EGF tissue profiles. In:Vahlensieck W, Rutishauser G, eds. Benign Prostate Diseases. Stuttgart, Germany: Thieme Verlag; 1992:120-128.
17. Ota Y, Shimoya K, Zhang Q, et al. The expression of secretory leukocyte protease inhibitor (SLPI) in the fallopian tube: SLPI protects the acrosome reaction of sperm from inhibitory effects of elastase. Hum Reprod. 2002;17:2517-2522.
18. Tanimoto H, Underwood LJ, Shigemasa K, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 1999;86:2074-2082.
19. Liang CZ, Guo QK, Hao ZY, et al. K channel expression in prostate epithelium and its implications in men with chronic prostatitis. BJU Int. 2006;97:190-192.
20. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, and the ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
21. Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 1999;45:1960-1966.
22. Xi Z, Klokk TI, Korkmaz K, Kurys P, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004;64:2365-2370.
23. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 2003;63:6543-6546.
24. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002;62:295-300.
25. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876-890.
26. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer. 2005;12:631-643.
27. Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer. 2007;109:1811-1820.
28. Debela M, Hess P, Magdolen V, et al. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7. Proc Natl Acad Sci U S A. 2007;104:16086-16091.
29. Lundström A, Egelrud T. Cell shedding from human plantar skin in vitro: evidence of its dependence on endogenous proteolysis. J Invest Dermatol. 1988;91:340-343.
30. Magklara A, Scorilas A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000;56:527-532.
31. Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem. 2000;46:896-900.